| Literature DB >> 33281391 |
Vibha Singh1, Abhaya Gupta2, Umesh Pratap Verma2, Tripti Mishra3, Mahesh Pal3.
Abstract
INTRODUCTION: Gingivitis is a relatively innocuous and reversible inflammation of gingiva. If left untreated, it might progress involving the deeper supporting periodontal tissues of the tooth with consequent mobility and tooth loss. Compelling literature has suggested the role of local antibacterial and anti‑inflammatory agents as an adjunct to scaling and root planing (gold standard) for treating periodontal diseases. Various herbs such as Nimba (Azadirachta indica A. Juss), Babbula (Vachellia nilotica (L.) P.J.H. Hurter & Mabb.) and turmeric (Curcuma longa L.) have been used for gingivitis since ancient times. Nigella sativa L. (Kalonji) is one such herb known for its remarkable anti‑inflammatory, antioxidant and antimicrobial properties and thus has been utilized in the present study. AIM: The aim of the study was to explore the clinical efficacy of different ethanolic solutions of N. sativa in moderate‑to‑severe gingivitis patients.Entities:
Keywords: Anti‑inflammatory; Nigella sativa (Kalonji); clinical study; gingivitis; split‑mouth
Year: 2020 PMID: 33281391 PMCID: PMC7685263 DOI: 10.4103/ayu.AYU_68_18
Source DB: PubMed Journal: Ayu ISSN: 0974-8520
Figure 1Group I1: Patients subjected to scaling and root planing. Group I2: Patients in which Kalonji solution (solution 1) with 1:3 ratio was applied topically on the surface of gingiva and gingival sulcus was irrigated with the same solution
Figure 3Group III1: Patients subjected to scaling and root planing. Group III2: Patients in which Kalonji solution (solution 3) with 3:1 ratio was applied topically on the surface of gingiva and gingival sulcus was irrigated with the same solution
Age and sex wise distribution of patients
| Group | Age | Sex, | ||||
|---|---|---|---|---|---|---|
| Mean±SD | Female | Male | ||||
| Group I | 28.00±6.856 | 0.349 | 0.710 | 4 (57.1) | 3 (42.9) | 0.854 |
| Group II | 28.29±7.994 | 3 (42.9) | 4 (57.1) | |||
| Group III | 30.86±6.176 | 2 (28.6) | 5 (71.4) | |||
| Total | 29.05±6.815 | 9 (42.9) | 12 (57.1) | |||
SD: Standard deviation
Comparison of gingival index among Groups I1 and I2, Groups II1 and II2, and Groups III1 and III2
| GI | Mean±SD | Mean±SD | Mean±SD | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Group I1 | Group I2 | Group II1 | Group II2 | Group III1 | Group III2 | ||||
| Baseline | 2.16±0.23 | 2.18±0.39 | 0.891 | 2.18±0.41 | 2.16±0.37 | 0.604 | 2.50±0.44 | 2.59±0.31 | 0.283 |
| 14th day | 0.59±0.17 | 1.88±0.32 | <0.001 | 1.11±0.39 | 1.73±0.27 | 0.001 | 1.23±0.35 | 1.79±0.39 | 0.004 |
| 28th day | 0.16±0.09 | 1.36±0.24 | <0.001 | 0.29±0.20 | 0.84±0.16 | <0.001 | 0.27±0.11 | 0.61±0.20 | 0.001 |
| Intragroup ( | 502.37, <0.001 | 51.25, <0.001 | 139.33, <0.001 | 84.95, <0.001 | 115.41, <0.001 | 153.75, <0.001 | |||
SD: Standard deviation, GI: Gingival index
Comparison of plaque index among Groups I1 and I2, Groups II1 and II2, and Groups III1 and III2
| PI | Mean±SD | Mean±SD | Mean±SD | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Group I1 | Group I2 | Group II1 | Group II2 | Group III1 | Group III2 | ||||
| Baseline | 2.04±0.30 | 1.96±0.34 | 0.436 | 2.07±0.19 | 2.16±0.21 | 0.182 | 2.34±0.20 | 2.43±0.28 | 0.054 |
| 14th day | 0.25±0.10 | 1.88±0.38 | <0.001 | 0.27±0.09 | 2.05±0.21 | <0.001 | 0.27±0.13 | 2.36±0.29 | <0.001 |
| 28th day | 0.30±0.10 | 1.77±0.34 | <0.001 | 0.20±0.10 | 2.02±0.25 | <0.001 | 0.16±0.09 | 2.25±0.25 | <0.001 |
| Intragroup ( | 260.06, <0.001 | 7.80, 0.007 | 419.25, <0.001 | 12.48, 0.001 | 575.19, <0.001 | 30.40, <0.001 | |||
SD: Standard deviation, PI: Plaque index